CymitQuimica logo

CAS 380843-75-4

:

Bosutinib

Description:
Bosutinib is a small molecule tyrosine kinase inhibitor primarily used in the treatment of chronic myelogenous leukemia (CML). It selectively inhibits the BCR-ABL fusion protein, which is responsible for the proliferation of cancer cells in CML. Bosutinib has a molecular formula that reflects its complex structure, featuring multiple functional groups that contribute to its pharmacological activity. The compound is characterized by its ability to inhibit not only BCR-ABL but also other kinases, which may lead to a broader spectrum of effects. It is typically administered orally and has a favorable pharmacokinetic profile, allowing for once-daily dosing. Common side effects associated with bosutinib include gastrointestinal disturbances, hematologic abnormalities, and liver enzyme elevations. Its efficacy and safety profile make it a valuable option in the therapeutic landscape for patients with resistant or intolerant forms of CML. As with all medications, monitoring for adverse effects and drug interactions is essential during treatment.
Formula:C26H29Cl2N5O3
InChI:InChI=1/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)
InChI key:InChIKey=UBPYILGKFZZVDX-UHFFFAOYSA-N
SMILES:N(C=1C2=C(C=C(OCCCN3CCN(C)CC3)C(OC)=C2)N=CC1C#N)C4=CC(OC)=C(Cl)C=C4Cl
Synonyms:
  • 3-Quinolinecarbonitrile, 4-[(2,4-dichloro-5-Methoxyphenyl)amino]-6-Methoxy-7-[3-(4-Methyl-1-piperazinyl)propoxy]-
  • 4-[(2,4-Dichloro-5-Methoxyphenyl)Amino]-6-Methoxy-7-[3-(4-Methylpiperazin-1-Yl)Propoxy]Quinoline-3-Carbonitrile
  • 4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile
  • Bosulif
  • Kin 001-160
  • Sk 606
  • Ski-606
  • Bosutinib
  • Bosutinib for research
Found 18 products.